Ainos enters VELDONA license deal, gets $600,000 upfront fee
Partner will fund development for the first two globally licensed indications, including Sjögren's disease and thrombocytopenia.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.